Have you heard?

There’s an easier way to treat otitis externa.

Introducing Neptra®

Neptra® is an effective new option for the treatment of acute canine otitis externa or acute exacerbations of recurrent otitis caused by mixed infections of susceptible strains of bacteria sensitive to florfenicol (Staphylococcus pseudintermedius) and fungi sensitive to terbinafine (Malassezia pachydermatis).

The ONLY first-line treatment available in ONE vet-administered dose.

Offering complete control over compliance in the treatment of otitis externa, Neptra removes the owner responsibility, stress and uncertainty of repeated at-home treatments.

Ideal for first-line use and effective against the most common pathogens* - associated with 70-80% of OE cases, make Neptra your first choice for OE treatment.

Watch Video

Successful managementof otitis externa

Canine otitis externa (OE) is common, affecting up to 1 in 5 dogs1 visiting your practice.

After otoscopic examination, successful management of OE requires cytology to be performed. When Malassezia pachydermatis and Staphylococcus pseudintermedius are identified reach for Neptra®.

Most vets will have experienced compliance issues with at-home, multiple dose OE treatments – something that Neptra's one dose, administered-by-the-vet formulation provides a solution for.

Neptra should not be reserved for 'difficult cases'. With its suitability for first-line use, proven efficacy against the most common pathogens associated with OE and elimination of owner compliance issues, make Neptra your first choice for treating OE.

Neptra
Neptra
Neptra
Neptra
Neptra
Neptra

Neptra® – a unique combination

Neptra® contains a unique combination of three active ingredients that work together to be effective against the most common pathogens associated with otitis externa, as well as providing potent anti-inflammatory and anti-pruritic action, giving welcome relief from the discomfort of OE.

The single-dose, easier solution for otitis externa

The single-dose, easier solution for otitis externa

NEW to the UK

Neptra® is the ONLY first-line treatment available in ONE vet-administered dose for canine otitis externa.

Its innovative formulation provides lasting action after one application, making the treatment of otitis externa easier for everyone.

Hear from the experts

Hear from the experts Watch Video

Otitis externa

with Dr Sarah Warren, BVetMed MSc CertVD MRCVS, President of BVDSG

Dr Sarah Warren details the challenges involved in treating otitis externa in dogs. There are many primary, predisposing and perpetuating factors which should be considered when managing the disease as these lead to or prevent resolution of secondary infection. Cytology is a useful, inexpensive tool that can be performed in house so you can have confidence knowing what infections you are treating – 70-80% of the time these are Staphylococcus pseudintermedius and Malassezia pachydermatis. As we know, owner compliance can often be poor with multidose treatments and Sarah discusses this.

Hear from the experts Watch Video

Neptra® - for first line use

with Dr Kenneth W. Kwochka, DVM, DACVD, President of the World Association of Dermatology

Dr. Ken Kwochka discusses why Neptra is an ideal first line product for the majority of Otitis externa cases which present with Staphylococcus pseudintermedius and Malassezia pachydermatis.

You've heard, have your clients?

We have a range of materials available to help you educate pet owners on otitis externa, and treatment with Neptra® once prescribed.

You've heard, have your clients?

* Staphylococcus pseudintermedius and Malassezia pachydermatis.

  1. Angus J. C. Vet Clinics of North America: Small Animal Practice. 2004 Mar;34(2):411-24.
  2. Dog Owner Compliance Evaluation, June 2019, n=2000 dog owners from FR/IT/ES/DE/NL/BE/UK/AU
  3. World Health Organization (WHO). (2011). Critically important antimicrobials for human medicine. 3rd Revision. Available at: http://www.who.int/iris/handle/10665/77376 Accessed March 20, 2019.
  4. Spada, F. et al. (2018) Australasian Journal of Dermatology 59(3): e168-e174
Send feedback